Bliss GVS Pharma Ltd's partner gets final approval from USFDA for Mesalamine Suppositories 1000 mg

Rising Pharma Holdings, Inc. USA, a marketing and distribution partner of Bliss GVS Pharma Limited ("the Company") has been granted final approval from the U.S. Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) for its product "Mesalamine Suppositories 1000 mg". The ANDA was submitted through our partner in the USA.

The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million for the twelve months ending January 2025, according to IQVIA.

"The ANDA approval for Mesalamine suppositories further strengthens our portfolio of differentiated OTC and Prescription products for the U.S. market. This approval is a testament to our capabilities to successfully develop and commercialize products using in-house R&D capabilities built over the last few years," commented Gagan Harsh Sharma, Managing Director, Bliss GVS Pharma Limited.

Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 124.20 as compared to the previous close of Rs. 119.05. The total number of shares traded during the day was 48632 in over 807 trades.

The stock hit an intraday high of Rs. 126.00 and intraday low of 120.55. The net turnover during the day was Rs. 5971040.00.

Source : Equity Bulls

Keywords

BlissGVSPharma INE416D01022 Partner RisingPharmaHoldingsInc USA USFDA FinalApproval ANDA MesalamineSuppositories 1000mg